Do analysts recommend TAK or NVO?

Novo Nordisk A/S has a consensus target price of $102.85, suggesting a potential upside of 173.94%. Given Novo Nordisk A/S's higher possible upside, analysts clearly believe Novo Nordisk A/S is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Novo Nordisk A/S 4 Sell rating(s) 17 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.07

Does the media prefer TAK or NVO?

In the previous week, Novo Nordisk A/S had 32 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 46 mentions for Novo Nordisk A/S and 14 mentions for Takeda Pharmaceutical. Novo Nordisk A/S's average media sentiment score of 0.31 beat Takeda Pharmaceutical's score of 0.12 indicating that Novo Nordisk A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Novo Nordisk A/S 19 Very Positive mention(s) 9 Positive mention(s) 8 Neutral mention(s) 8 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts recommend PFE or TAK?

Pfizer currently has a consensus target price of $28.39, suggesting a potential upside of 3.55%. Given Pfizer's higher possible upside, analysts plainly believe Pfizer is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pfizer 2 Sell rating(s) 14 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.19 Takeda Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50

Does the media favor PFE or TAK?

In the previous week, Pfizer had 47 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 61 mentions for Pfizer and 14 mentions for Takeda Pharmaceutical. Pfizer's average media sentiment score of 0.35 beat Takeda Pharmaceutical's score of 0.12 indicating that Pfizer is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pfizer 24 Very Positive mention(s) 10 Positive mention(s) 20 Neutral mention(s) 5 Negative mention(s) 2 Very Negative mention(s) Neutral Takeda Pharmaceutical 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer TAK or BMY?

Bristol Myers Squibb has a consensus target price of $67.00, indicating a potential upside of 14.08%. Given Bristol Myers Squibb's stronger consensus rating and higher possible upside, analysts plainly believe Bristol Myers Squibb is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Bristol Myers Squibb 1 Sell rating(s) 11 Hold rating(s) 11 Buy rating(s) 2 Strong Buy rating(s) 2.56

Does the media favor TAK or BMY?

In the previous week, Bristol Myers Squibb had 18 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 32 mentions for Bristol Myers Squibb and 14 mentions for Takeda Pharmaceutical. Bristol Myers Squibb's average media sentiment score of 0.61 beat Takeda Pharmaceutical's score of 0.12 indicating that Bristol Myers Squibb is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Bristol Myers Squibb 10 Very Positive mention(s) 8 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 3 Very Negative mention(s) Positive

Do analysts rate TAK or SNY?

Sanofi has a consensus target price of $49.50, suggesting a potential upside of 25.28%. Given Sanofi's higher probable upside, analysts clearly believe Sanofi is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Sanofi 1 Sell rating(s) 10 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 2.38

Does the media favor TAK or SNY?

In the previous week, Takeda Pharmaceutical and Takeda Pharmaceutical both had 14 articles in the media. Sanofi's average media sentiment score of 0.46 beat Takeda Pharmaceutical's score of 0.12 indicating that Sanofi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Sanofi 3 Very Positive mention(s) 5 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer GSK or TAK?

GSK currently has a consensus target price of $56.50, indicating a potential upside of 21.39%. Given GSK's higher possible upside, research analysts plainly believe GSK is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GSK 2 Sell rating(s) 7 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.09 Takeda Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has stronger valuation and earnings, GSK or TAK?

GSK has higher revenue and earnings than Takeda Pharmaceutical. GSK is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GSK $33.20B 2.84 $7.54B $3.20 14.55 Takeda Pharmaceutical $28.32B 2.02 -$1.01B $0.34 52.43

Does the media favor GSK or TAK?

In the previous week, Takeda Pharmaceutical had 9 more articles in the media than GSK. MarketBeat recorded 14 mentions for Takeda Pharmaceutical and 5 mentions for GSK. Takeda Pharmaceutical's average media sentiment score of 0.12 beat GSK's score of -0.04 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Takeda Pharmaceutical 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral

Takeda Pharmaceutical (TAK) Competitors

$18.11 +0.31 (+1.71%)

Closing price 03:59 PM Eastern

Extended Trading

$17.87 -0.24 (-1.33%)

As of 07:57 PM Eastern

Compare

TAK vs. NVO, PFE, BMY, SNY, and GSK

Should you buy Takeda Pharmaceutical stock or one of its competitors? Takeda Pharmaceutical's main competitors and comparable companies include Novo Nordisk A/S (NVO), Pfizer (PFE), Bristol Myers Squibb (BMY), Sanofi (SNY), and GSK (GSK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Takeda Pharmaceutical compare to Novo Nordisk A/S?

Takeda Pharmaceutical (NYSE:TAK) and Novo Nordisk A/S (NYSE:NVO) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.

Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.7%. Novo Nordisk A/S pays an annual dividend of $0.82 per share and has a dividend yield of 2.2%. Takeda Pharmaceutical pays out 141.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Novo Nordisk A/S pays out 20.0% of its earnings in the form of a dividend.

Novo Nordisk A/S has a net margin of 35.36% compared to Takeda Pharmaceutical's net margin of 3.80%. Novo Nordisk A/S's return on equity of 58.61% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	3.80%	10.95%	5.34%
Novo Nordisk A/S	35.36%	58.61%	20.91%

Takeda Pharmaceutical has a beta of -0.07, suggesting that its stock price is 107% less volatile than the broader market. Comparatively, Novo Nordisk A/S has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market.

Novo Nordisk A/S has a consensus target price of $102.85, suggesting a potential upside of 173.94%. Given Novo Nordisk A/S's higher possible upside, analysts clearly believe Novo Nordisk A/S is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Novo Nordisk A/S	4 Sell rating(s)	17 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.07

In the previous week, Novo Nordisk A/S had 32 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 46 mentions for Novo Nordisk A/S and 14 mentions for Takeda Pharmaceutical. Novo Nordisk A/S's average media sentiment score of 0.31 beat Takeda Pharmaceutical's score of 0.12 indicating that Novo Nordisk A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
Novo Nordisk A/S	19 Very Positive mention(s)	9 Positive mention(s)	8 Neutral mention(s)	8 Negative mention(s)	1 Very Negative mention(s)	Neutral

9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Novo Nordisk A/S has higher revenue and earnings than Takeda Pharmaceutical. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.32B	2.02	-$1.01B	$0.34	52.43
Novo Nordisk A/S	$46.80B	3.58	$15.51B	$4.09	9.18

Summary

Novo Nordisk A/S beats Takeda Pharmaceutical on 15 of the 18 factors compared between the two stocks.

How does Takeda Pharmaceutical compare to Pfizer?

Pfizer (NYSE:PFE) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation.

Pfizer has higher revenue and earnings than Takeda Pharmaceutical. Pfizer is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$62.58B	2.50	$7.77B	$0.76	36.07
Takeda Pharmaceutical	$28.32B	2.02	-$1.01B	$0.34	52.43

68.4% of Pfizer shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 0.6% of Pfizer shares are owned by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Pfizer has a net margin of 6.80% compared to Takeda Pharmaceutical's net margin of 3.80%. Pfizer's return on equity of 19.63% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	6.80%	19.63%	8.46%
Takeda Pharmaceutical	3.80%	10.95%	5.34%

Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.3%. Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.7%. Pfizer pays out 226.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Takeda Pharmaceutical pays out 141.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer has raised its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Pfizer has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.07, indicating that its stock price is 107% less volatile than the broader market.

Pfizer currently has a consensus target price of $28.39, suggesting a potential upside of 3.55%. Given Pfizer's higher possible upside, analysts plainly believe Pfizer is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	2 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.19
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Pfizer had 47 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 61 mentions for Pfizer and 14 mentions for Takeda Pharmaceutical. Pfizer's average media sentiment score of 0.35 beat Takeda Pharmaceutical's score of 0.12 indicating that Pfizer is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	24 Very Positive mention(s)	10 Positive mention(s)	20 Neutral mention(s)	5 Negative mention(s)	2 Very Negative mention(s)	Neutral
Takeda Pharmaceutical	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Pfizer beats Takeda Pharmaceutical on 17 of the 20 factors compared between the two stocks.

How does Takeda Pharmaceutical compare to Bristol Myers Squibb?

Takeda Pharmaceutical (NYSE:TAK) and Bristol Myers Squibb (NYSE:BMY) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.

Takeda Pharmaceutical has a beta of -0.07, suggesting that its stock price is 107% less volatile than the broader market. Comparatively, Bristol Myers Squibb has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market.

9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 76.4% of Bristol Myers Squibb shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Comparatively, 0.1% of Bristol Myers Squibb shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Bristol Myers Squibb has higher revenue and earnings than Takeda Pharmaceutical. Bristol Myers Squibb is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.32B	2.02	-$1.01B	$0.34	52.43
Bristol Myers Squibb	$48.19B	2.49	$7.05B	$4.54	12.94

Bristol Myers Squibb has a net margin of 18.87% compared to Takeda Pharmaceutical's net margin of 3.80%. Bristol Myers Squibb's return on equity of 66.90% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	3.80%	10.95%	5.34%
Bristol Myers Squibb	18.87%	66.90%	14.74%

Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.7%. Bristol Myers Squibb pays an annual dividend of $2.52 per share and has a dividend yield of 4.3%. Takeda Pharmaceutical pays out 141.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Bristol Myers Squibb pays out 55.5% of its earnings in the form of a dividend. Bristol Myers Squibb has increased its dividend for 17 consecutive years. Bristol Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Bristol Myers Squibb has a consensus target price of $67.00, indicating a potential upside of 14.08%. Given Bristol Myers Squibb's stronger consensus rating and higher possible upside, analysts plainly believe Bristol Myers Squibb is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Bristol Myers Squibb	1 Sell rating(s)	11 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.56

In the previous week, Bristol Myers Squibb had 18 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 32 mentions for Bristol Myers Squibb and 14 mentions for Takeda Pharmaceutical. Bristol Myers Squibb's average media sentiment score of 0.61 beat Takeda Pharmaceutical's score of 0.12 indicating that Bristol Myers Squibb is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bristol Myers Squibb	10 Very Positive mention(s)	8 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	3 Very Negative mention(s)	Positive

Summary

Bristol Myers Squibb beats Takeda Pharmaceutical on 19 of the 20 factors compared between the two stocks.

How does Takeda Pharmaceutical compare to Sanofi?

Takeda Pharmaceutical (NYSE:TAK) and Sanofi (NASDAQ:SNY) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

Sanofi has a net margin of 8.66% compared to Takeda Pharmaceutical's net margin of 3.80%. Sanofi's return on equity of 14.19% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	3.80%	10.95%	5.34%
Sanofi	8.66%	14.19%	7.95%

Sanofi has higher revenue and earnings than Takeda Pharmaceutical. Sanofi is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.32B	2.02	-$1.01B	$0.34	52.43
Sanofi	$49.35B	1.94	$8.84B	$1.91	20.69

Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.7%. Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.5%. Takeda Pharmaceutical pays out 141.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Sanofi pays out 92.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Sanofi is clearly the better dividend stock, given its higher yield and lower payout ratio.

In the previous week, Takeda Pharmaceutical and Takeda Pharmaceutical both had 14 articles in the media. Sanofi's average media sentiment score of 0.46 beat Takeda Pharmaceutical's score of 0.12 indicating that Sanofi is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sanofi	3 Very Positive mention(s)	5 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sanofi has a consensus target price of $49.50, suggesting a potential upside of 25.28%. Given Sanofi's higher probable upside, analysts clearly believe Sanofi is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Sanofi	1 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.38

9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by insiders. Comparatively, 1.0% of Sanofi shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Takeda Pharmaceutical has a beta of -0.07, meaning that its stock price is 107% less volatile than the broader market. Comparatively, Sanofi has a beta of 0.33, meaning that its stock price is 67% less volatile than the broader market.

Summary

Sanofi beats Takeda Pharmaceutical on 15 of the 18 factors compared between the two stocks.

How does Takeda Pharmaceutical compare to GSK?

GSK (NYSE:GSK) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

GSK currently has a consensus target price of $56.50, indicating a potential upside of 21.39%. Given GSK's higher possible upside, research analysts plainly believe GSK is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	2 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.09
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

GSK has a net margin of 14.56% compared to Takeda Pharmaceutical's net margin of 3.80%. GSK's return on equity of 43.23% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	14.56%	43.23%	11.60%
Takeda Pharmaceutical	3.80%	10.95%	5.34%

GSK has higher revenue and earnings than Takeda Pharmaceutical. GSK is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$33.20B	2.84	$7.54B	$3.20	14.55
Takeda Pharmaceutical	$28.32B	2.02	-$1.01B	$0.34	52.43

GSK pays an annual dividend of $1.77 per share and has a dividend yield of 3.8%. Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.7%. GSK pays out 55.3% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 141.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.

GSK has a beta of 0.33, indicating that its stock price is 67% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.07, indicating that its stock price is 107% less volatile than the broader market.

In the previous week, Takeda Pharmaceutical had 9 more articles in the media than GSK. MarketBeat recorded 14 mentions for Takeda Pharmaceutical and 5 mentions for GSK. Takeda Pharmaceutical's average media sentiment score of 0.12 beat GSK's score of -0.04 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Takeda Pharmaceutical	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

15.7% of GSK shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 10.0% of GSK shares are owned by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

GSK beats Takeda Pharmaceutical on 14 of the 19 factors compared between the two stocks.

Get Takeda Pharmaceutical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TAK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TAK vs. The Competition

Export

Metric	Takeda Pharmaceutical	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$57.07B	$12.19B	$7.19B	$22.91B
Dividend Yield	2.70%	2.65%	2.53%	3.73%
P/E Ratio	53.28	643.32	204.51	23.77
Price / Sales	2.05	748.79	582.81	21.16
Price / Cash	5.74	87.12	79.41	36.95
Price / Book	1.18	10.63	11.04	4.72
Net Income	-$1.01B	$2.84B	$3.49B	$1.07B
7 Day Performance	-2.00%	-2.19%	-2.30%	0.89%
1 Month Performance	-1.87%	-6.91%	-7.05%	-4.97%
1 Year Performance	24.42%	-4.98%	5.64%	5.65%

Takeda Pharmaceutical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TAK Takeda Pharmaceutical	1.4664 of 5 stars	$18.12 +1.7%	N/A	+22.0%	$57.07B	$28.32B	53.28	47,000
NVO Novo Nordisk A/S	4.4078 of 5 stars	$38.69 -0.3%	$64.94 +67.8%	-37.1%	$173.24B	$46.80B	9.46	69,505	Trending News
PFE Pfizer	3.0074 of 5 stars	$28.76 +0.3%	$28.39 -1.3%	+0.2%	$163.41B	$62.58B	37.84	75,000	Trending News Analyst Forecast
BMY Bristol Myers Squibb	4.7981 of 5 stars	$63.84 +1.6%	$67.06 +5.0%	+29.4%	$128.41B	$48.19B	14.06	32,500	Trending News Analyst Downgrade Gap Down
SNY Sanofi	4.0496 of 5 stars	$41.18 +0.2%	$49.50 +20.2%	-22.4%	$99.67B	$49.35B	21.56	74,846	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:TAK) was last updated on 10/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Takeda Pharmaceutical (TAK) Competitors

TAK vs. NVO, PFE, BMY, SNY, and GSK

How does Takeda Pharmaceutical compare to Novo Nordisk A/S?

Summary

How does Takeda Pharmaceutical compare to Pfizer?

Summary

How does Takeda Pharmaceutical compare to Bristol Myers Squibb?

Summary

How does Takeda Pharmaceutical compare to Sanofi?

Summary

How does Takeda Pharmaceutical compare to GSK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TAK vs. The Competition

Takeda Pharmaceutical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Takeda Pharmaceutical (TAK) Competitors

TAK vs. NVO, PFE, BMY, SNY, and GSK

How does Takeda Pharmaceutical compare to Novo Nordisk A/S?

Is TAK or NVO a better dividend stock?

Is TAK or NVO more profitable?

Which has more risk and volatility, TAK or NVO?

Do analysts recommend TAK or NVO?

Does the media prefer TAK or NVO?

Do insiders and institutionals hold more shares of TAK or NVO?

Which has better earnings & valuation, TAK or NVO?

Summary

How does Takeda Pharmaceutical compare to Pfizer?

Which has preferable earnings & valuation, PFE or TAK?

Do insiders and institutionals hold more shares of PFE or TAK?

Is PFE or TAK more profitable?

Is PFE or TAK a better dividend stock?

Which has more risk and volatility, PFE or TAK?

Do analysts recommend PFE or TAK?

Does the media favor PFE or TAK?

Summary

How does Takeda Pharmaceutical compare to Bristol Myers Squibb?

Which has more volatility & risk, TAK or BMY?

Do insiders and institutionals hold more shares of TAK or BMY?

Which has preferable earnings and valuation, TAK or BMY?

Is TAK or BMY more profitable?

Is TAK or BMY a better dividend stock?

Do analysts prefer TAK or BMY?

Does the media favor TAK or BMY?

Summary

How does Takeda Pharmaceutical compare to Sanofi?

Is TAK or SNY more profitable?

Which has preferable valuation and earnings, TAK or SNY?

Is TAK or SNY a better dividend stock?

Does the media favor TAK or SNY?

Do analysts rate TAK or SNY?

Do institutionals & insiders have more ownership in TAK or SNY?

Which has more volatility and risk, TAK or SNY?

Summary

How does Takeda Pharmaceutical compare to GSK?

Do analysts prefer GSK or TAK?

Is GSK or TAK more profitable?

Which has stronger valuation and earnings, GSK or TAK?

Is GSK or TAK a better dividend stock?

Which has more risk & volatility, GSK or TAK?

Does the media favor GSK or TAK?

Do institutionals & insiders have more ownership in GSK or TAK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TAK vs. The Competition

Takeda Pharmaceutical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools